Metabolic effects of contraceptive implants in adolescents

Metabolic effects of contraceptive implants in adolescents

Author Guazzelli, Cristina A. F. Autor UNIFESP Google Scholar
Queiroz, Flaviano Teixeira de Autor UNIFESP Google Scholar
Barbieri, Marcia Autor UNIFESP Google Scholar
Barreiros, Fernando A. Autor UNIFESP Google Scholar
Torloni, Maria Regina Autor UNIFESP Google Scholar
Araujo, Fabio F. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Background: This prospective study analyzed the metabolic effects of an etonogestrel implant used for 1 year by adolescents.Study Design: the study population comprised 47 postpartum adolescents (mean 17.2 years old) managed at the Family Planning Sector of São Paulo Federal University. Participants received an implant containing etonogestrel (68 mg) within 6 months of delivery (on average 102 days after giving birth) and were followed for 1 year. Blood was collected at baseline and 12 months later to assess total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), hemogram, urea, creatinine, sodium, potassium, fasting glucose, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and bilirubin.Results: Three adolescents did not return after receiving the implant despite telephone messages and a telegram and were excluded from the clinical and final laboratory analyses. All 44 patients completed the 12 months of follow-up, resulting in a study discontinuation rate of 0%. No implants were removed. Laboratory analyses were completed in 37 adolescents. After 1 year of using the implant, there was a significant increase in mean hemoglobin, hematocrit and indirect bilirubin concentrations and of the HDL-C/TC and HDL-C/LDL-C ratios. Additionally, there was a significant decrease in mean TC level as well as LDL-C, very low-density lipoprotein cholesterol, TG, SGOT and SGPT. These results suggest that the etonogestrel implant does not interfere directly with the risk of cardiovascular diseases because it improves the lipid profile. There were no pregnancies during the study.Conclusion: Our results indicate that an etonogestrel implant used by adolescents for 1 year is associated with changes in the lipid profile and hepatic function without adverse clinical effects. (C) 2011 Published by Elsevier Inc.
Keywords Etonogestrel
Contraceptive
Lipid metabolism
Adolescent
Hemoglobin
Liver function tests
Language English
Date 2011-10-01
Published in Contraception. New York: Elsevier B.V., v. 84, n. 4, p. 409-412, 2011.
ISSN 0010-7824 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 409-412
Origin http://dx.doi.org/10.1016/j.contraception.2011.02.006
Access rights Closed access
Type Article
Web of Science ID WOS:000295557900011
URI http://repositorio.unifesp.br/handle/11600/34104

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account